Vivo Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Vivo Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-626,401	Closed	-$2.46M	–	48
2019 Q2	$2.46M	Sell	626,401 -350,000	-36%	-$1.83M	0.23%	39
2019 Q1	$4.61M	Sell	976,401 -46,099	-5%	-$228K	0.46%	38
2018 Q4	$2.35M	Hold	1,022,500	–	–	0.3%	35
2018 Q3	$6.38M	Hold	1,022,500	–	–	0.64%	31
2018 Q2	$7M	Hold	1,022,500	–	–	0.9%	26
2018 Q1	$8.59M	Buy	+1,022,500	New	+$8.49M	1.22%	19

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vivo Capital's GNCA Position: Q3 2019 in Review

Vivo Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2019, closing a stake of 626,401 shares — an estimated $2.46M sold.

Vivo Capital first reported a position in GNCA in Q1 2018 and held it in 6 quarters. The position peaked at $8.59M in Q1 2018. 37 funds tracked by Wall St. Rank hold GNCA as of Q3 2019.

Vivo Capital reported no remaining Genocea Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
Vivo Capital sold 626,401 Genocea Biosciences, Inc. shares in Q3 2019, an estimated $2.46M.
Vivo Capital first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 6 quarters.
Vivo Capital's Genocea Biosciences, Inc. position peaked at $8.59M in Q1 2018.
37 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2019.

Based on Vivo Capital's 13F filing for Q3 2019, filed 13 Nov 2019.